Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06574360
PHASE2

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Sponsor: China Medical University Hospital

View on ClinicalTrials.gov

Summary

sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2024-09-23

Completion Date

2029-03

Last Updated

2026-03-24

Healthy Volunteers

No

Conditions

Interventions

DRUG

S1RA plus NMDAE

Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.

DRUG

S1RA plus Placebo Cap

Use of an S1R agonist plus placebo as a comparator

Locations (1)

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan